Sugi Predict

Sugi Predict / Compounds / SCHEMBL4358164

SCHEMBL4358164

SCHEMBL4358164

O=C(CC1CCN(S(=O)(=O)c2cccnc2)CC1)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 8/20 0.48
▸ HTT P42858 3/20 0.42
▸ POLB P06746 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ CHRNB2 P17787 1/20 0.38
▸ CHRNA4 P43681 1/20 0.38
▸ STK4 Q13043 1/20 0.37
▸ STK3 Q13188 1/20 0.37
▸ STK26 Q9P289 1/20 0.37
▸ STK24 Q9Y6E0 1/20 0.37
▸ JAK2 O60674 3/20 0.37
▸ JAK1 P23458 3/20 0.37
▸ TYK2 P29597 3/20 0.37
▸ JAK3 P52333 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4360250 0.96 ALK (0.45) ALKHTTPOLBSMN1; SMN2TSHR
SCHEMBL1074711 0.95 ALK (0.42) ALKHTTPOLBSMN1; SMN2TSHR
SCHEMBL13622647 0.93 ALK (0.51) ALKSTK4STK3STK26STK24
Trifluoroacetic Acid SCHEMBL4361804 0.90 HTT (0.40) ALKHTTPOLBTSHRKDM4E
SCHEMBL1076794 0.90 ALK (0.52) ALKSTK4STK3STK26STK24
SCHEMBL13669865 0.90 ALK (0.49) ALKSTK4STK3STK26STK24
SCHEMBL1075032 0.90 ALK (0.53) ALKSTK4STK3STK26STK24
Trifluoroacetic Acid SCHEMBL1076445 0.89 ALK (0.47) ALKSTK4STK3STK26STK24
SCHEMBL13622663 0.89 ALK (0.48) ALKPOLBSMN1; SMN2
SCHEMBL1075371 0.88 ALK (0.43) ALKHTTJAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 — — US claimed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 — — US claimed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 — — US disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 — — US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 — — US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 — — US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK ALK 3/4885HTT 2476/4885POLB 2346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.